Compare EVCM & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVCM | VERA |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 3.0B |
| IPO Year | 2021 | 2021 |
| Metric | EVCM | VERA |
|---|---|---|
| Price | $7.92 | $35.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $10.67 | ★ $81.30 |
| AVG Volume (30 Days) | 133.2K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.45 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $588,907,000.00 | N/A |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $5.84 | $472.48 |
| P/E Ratio | $90.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.66 | $22.72 |
| 52 Week High | $14.41 | $56.05 |
| Indicator | EVCM | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 28.50 | 54.64 |
| Support Level | N/A | $33.43 |
| Resistance Level | $12.45 | $37.13 |
| Average True Range (ATR) | 0.43 | 1.69 |
| MACD | -0.17 | 0.48 |
| Stochastic Oscillator | 14.20 | 71.31 |
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. The Company served more than 745,000 customers across three core verticals: EverPro for Home Services; EverHealth for Health Services; and EverWell for Wellness Services. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.